全文获取类型
收费全文 | 18044篇 |
免费 | 1236篇 |
国内免费 | 413篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 407篇 |
妇产科学 | 275篇 |
基础医学 | 3427篇 |
口腔科学 | 556篇 |
临床医学 | 1092篇 |
内科学 | 2970篇 |
皮肤病学 | 424篇 |
神经病学 | 1189篇 |
特种医学 | 236篇 |
外科学 | 2598篇 |
综合类 | 1719篇 |
现状与发展 | 1篇 |
预防医学 | 1070篇 |
眼科学 | 188篇 |
药学 | 1821篇 |
3篇 | |
中国医学 | 449篇 |
肿瘤学 | 1166篇 |
出版年
2023年 | 245篇 |
2022年 | 338篇 |
2021年 | 581篇 |
2020年 | 504篇 |
2019年 | 867篇 |
2018年 | 758篇 |
2017年 | 642篇 |
2016年 | 541篇 |
2015年 | 629篇 |
2014年 | 1024篇 |
2013年 | 1144篇 |
2012年 | 833篇 |
2011年 | 1149篇 |
2010年 | 923篇 |
2009年 | 932篇 |
2008年 | 799篇 |
2007年 | 883篇 |
2006年 | 852篇 |
2005年 | 708篇 |
2004年 | 650篇 |
2003年 | 533篇 |
2002年 | 399篇 |
2001年 | 297篇 |
2000年 | 291篇 |
1999年 | 230篇 |
1998年 | 201篇 |
1997年 | 156篇 |
1996年 | 163篇 |
1995年 | 140篇 |
1994年 | 103篇 |
1993年 | 91篇 |
1992年 | 79篇 |
1991年 | 73篇 |
1990年 | 63篇 |
1989年 | 53篇 |
1988年 | 45篇 |
1987年 | 55篇 |
1986年 | 52篇 |
1985年 | 189篇 |
1984年 | 225篇 |
1983年 | 183篇 |
1982年 | 213篇 |
1981年 | 170篇 |
1980年 | 143篇 |
1979年 | 149篇 |
1978年 | 87篇 |
1977年 | 66篇 |
1976年 | 61篇 |
1975年 | 68篇 |
1974年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 22 毫秒
1.
目的 分析10-MDP-钙盐形成对牙本质粘接成绩的影响。方法 采用酸蚀冲洗粘接模式,根据牙本质表面的处理方式和选择粘接剂的不同将牙齿随机分为以下4组(n=5)进行处理,制作牙本质/树脂粘接试件:①对照组,直接使用全酸蚀粘接剂Single bond 2(SB2)处理后粘接;②10-MDP组,使用SB2处理进行粘接前,牙本质表面以含有磷酸酯单体10-MDP的自配底涂剂预处理;③CHX组,使用SB2处理进行粘接前,先以氯己定(CHX)预处理牙本质表面;④SBU组,使用包含10-MDP的通用型粘接剂Single bond universal(SBU)处理后进行粘接。通过微拉伸测试(μTBS)测试粘接强度,以X射线衍射(XRD)、原位酶谱测试表征自配10-MDP底涂剂和两种牙本质粘接剂处理的牙本质表面,分析10-MDP-钙盐形成对牙本质粘接成绩的影响。结果 微拉伸结果显示,不同处理方式的粘接试件在24 h水储后没有表现出明显的统计学差异(P>0.1);经过6个月的水储后,与10-MDP组和SBU组相比,对照组的微拉伸强度显著降低(P<0.05),而CHX组的微拉伸强度没有明显变化(P>0.05)。XRD结果显示,在10-MDP组和SBU组均检测到10-MDP-钙盐形成的特征性峰,表明有10-MDP-钙盐的形成。原位酶谱结果显示,10-MDP组与SBU组之间混合层荧光强度没有明显区别,但均明显高于对照组,CHX组荧光强度低于10-MDP组与SBU组。结论 10-MDP-钙盐的形成能够保护暴露的胶原纤维不接触到MMPs而免于水解,从而增强牙本质/树脂的粘接成绩。 相似文献
2.
3.
4.
�� �������������������л �� 《中国实用口腔科杂志》2015,8(11):679-682
??Objective To discuss the influence of basic periodontal therapy on the level of IL-8?? IL-10 in serum and gingival crevicular fluid in patients who have chronic periodontitis complicated by coronary heart disease. Methods A total of 65 cases of patients with chronic periodontitis complicated by coronary heart disease were selected and divided into two groups randomly??Group A of 35 patients who received the basic periodontal therapy and cardiac medical treatment??Group B of 30 patients who received cardiological treatment only. Then??select 25 patient who had developed chronic severe periodontitis with non-systematic disease to establish group C and give them the basic periodontal therapy only. Observe the changes of the IL-8??IL-10 levels in serum and gingival crevicular fluid and the periodontal infection indexes??BI??PD??. Results The results showed that after three months of basic periodontal therapy the periodontal clinical indices of both group A and group C became better and the IL-8 level obviously reduced??while the IL-10 level obviously increased. There was no obvious difference between group A and group B in each examination index before the therapy. After three months??we found that the periodontal infection index??SBI PD??of group A was obviously better than group B. Compared to group B??the IL-8 level of group A obviously reduced??and the IL-10 level obviously increased. The difference was statistically significant??P < 0.05??. Conclusion The basic periodontal therapy can effectively improve periodontal conditions of the patients with chronic periodontal diseases??and reduce the risk of breaking the normal cardiovascular function. 相似文献
5.
《Clinical neurophysiology》2020,131(1):259-264
ObjectivesFasciculation potentials (FP) are an important consideration in the electrophysiological diagnosis of ALS. Muscle ultrasonography (MUS) has a higher sensitivity in detecting fasciculations than electromyography (EMG), while in some cases, it is unable to detect EMG-detected fasciculations. We aimed to investigate the differences of FP between the muscles with and without MUS-detected fasciculations (MUS-fas).MethodsThirty-one consecutive patients with sporadic ALS were prospectively recruited and in those, both needle EMG and MUS were performed. Analyses of the amplitude, duration, and number of phases of EMG-detected FPs were performed for seven muscles per patient, and results were compared between the muscles with and without MUS-fas in the total cohort.ResultsThe mean amplitude and phase number of FP were significantly lower in patients with EMG-detected FP alone (0.39 ± 0.25 mV and 3.21 ± 0.88, respectively) than in those with both FP and MUS-fas (1.22 ± 0.92 mV and 3.74 ± 1.39, respectively; p < 0.0001 and p = 0.017, Welch’s t-test).ConclusionSmall FP may be undetectable with MUS. MUS cannot replace EMG in the diagnostic approach for ALS.SignificanceClinicians should use a combination of EMG and MUS for the detection and quantitative analysis of fasciculation in ALS. 相似文献
6.
7.
8.
Ngai-Yin Chan Chi-Chung Choy Ho-Chuen Yuen Hoi-Fan Chow Ho-Fai Fong 《The Canadian journal of cardiology》2019,35(4):396-404
Background
Persistent iatrogenic atrial septal defect (iASD) is a common but poorly characterized complication after cryoballoon (CB) pulmonary vein isolation (PVI) procedures. We therefore investigate its prevalence, evolution, risk factors, and clinical outcomes in a prospective longitudinal study.Methods
A total of 108 patients (41 women, mean age 57 ± 11.3) underwent CB PVI for AF. Serial transesophageal echocardiography (TEE) was performed 9 months and then annually until 6 years after the procedure to study the characteristics of persistent iASD.Results
Persistent iASD occurred in 33 (30.6%) patients 9 months after CB PVI. Spontaneous closure of iASD was found in 6 (22.2%) and 3 (15.8%) patients 2 and 3 years after the procedures, respectively. No spontaneous closure was observed on 4, 5, and 6-year TEE follow-up. The projected long-term persistence rate of iASD after CB PVI was therefore 20% (30.6% × 0.778 × 0.842). Using multivariate logistic regression, a higher number of cryoapplications (≥ 2 minutes) was the only independent predictor of persistent iASD 9 months after CB PVI (odds ratio [OR] 1.207; 95% confidence interval [CI], 1.033-1.411, P = 0.018). Two (1.9%) patients with significantly larger iASD size than the others (long diameter 12.6 ± 0.8 vs 3.7 ± 1.5 mm, P < 0.001; short diameter 10.9 ± 0.2 vs 3 ± 1.1 mm, P < 0.001) required percutaneous closure because of exertional dyspnea and right ventricular enlargement. Over 129.7 patient-years follow-up, during which iASD persisted, there was no occurrence of neurologic events.Conclusions
Approximately one fifth of patients undergoing CB PVI will have permanently persistent iASD. Patients with defect sizes of greater than 10 mm may need percutaneous closure due to significant left-to-right shunting. 相似文献9.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
10.
《Vaccine》2016,34(30):3500-3507
We describe the preclinical development of a dengue virus vaccine targeting the dengue virus serotype 2 (DENV2) envelope domain III (EDIII). This study provides proof-of-principle that a dengue EDIII protein scaffold/DNA vaccine can protect against dengue challenge. The dengue vaccine (EDIII-E2) is composed of both a protein particle and a DNA expression plasmid delivered simultaneously via intramuscular injection (protein) and gene gun (DNA) into rhesus macaques. The protein component can contain a maximum of 60 copies of EDIII presented on a multimeric scaffold of Geobacillus stearothermophilus E2 proteins. The DNA component is composed of the EDIII portion of the envelope gene cloned into an expression plasmid. The EDIII-E2 vaccine elicited robust antibody responses to DENV2, with neutralizing antibody responses detectable following the first boost and reaching titers of greater than 1:100,000 following the second and final boost. Vaccinated and naïve groups of macaques were challenged with DENV2. All vaccinated macaques were protected from detectable viremia by infectious assay, while naïve animals had detectable viremia for 2–7 days post-challenge. All naïve macaques had detectable viral RNA from day 2–10 post-challenge. In the EDIII-E2 group, three macaques were negative for viral RNA and three were found to have detectable viral RNA post challenge. Viremia onset was delayed and the duration was shortened relative to naïve controls. The presence of viral RNA post-challenge corresponded to a 10–30-fold boost in neutralization titers 28 days post challenge, whereas no boost was observed in the fully protected animals. Based on these results, we determine that pre-challenge 50% neutralization titers of >1:6000 correlated with sterilizing protection against DENV2 challenge in EDIII-E2 vaccinated macaques. Identification of the critical correlate of protection for the EDIII-E2 platform in the robust non-human primate model lays the groundwork for further development of a tetravalent EDIII-E2 dengue vaccine. 相似文献